YANTAI, China, November 1, 2022 /PRNewswire/ — RemeGen Co.,Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, recently published data from the Phase II clinical trial of its own company’s novel fusion protein telitacicept for the treatment of myasthenia gravis ( MG) in Chinese patients with positive results.
In the multi-centre, randomized, open-label Phase II clinical trial, subjects were adult patients diagnosed with myasthenia gravis (MG), who tested positive for acetylcholine receptor antibodies and who were receiving standard medical therapy. With a once-weekly dosing cycle for 24 weeks, a total of 41 patients were enrolled, 29 of whom were randomly assigned to the study (14 to the 160 mg telitacicept group and 15 to the 240 mg group) and all completed the study Study from full term. The primary efficacy endpoint of the study was change from baseline in the quantitative Myasthenia Gravis (QMG) test score at week 24.
The study showed an average reduction of 7.7 points in the telitacicept 160 mg group and 9.6 points in the telitacicept 240 mg group (a 3-point improvement in the QMG score is clinically significant, with an improvement of more than 5 points represents a significant healing effect). It showed that telitacicept can significantly improve patients’ condition and showed good safety in the treatment of myasthenia gravis (MG).
“As a fully integrated biopharmaceutical company dedicated to the discovery, development and commercialization of innovative and differentiated biologics to treat autoimmune, oncology and ophthalmic diseases, our vision to become a leading player in the global biopharmaceutical industry is rapidly being realized. ” said dr Jianmin Fang, CEO and Chief Scientific Officer of RemeGen.
“By leveraging our strong research and development platforms, we have discovered and developed a robust pipeline of more than ten drug candidates, including…
